PRENOXDIAZINE HCL

Prenoxdiazine HCl is a peripheral antitussive that decreases cough receptor sensitivity in the respiratory tract without CNS depression. It is used for dry, non‑productive cough. Side effects include nausea, drowsiness, dizziness, and rare hypersensitivity reactions.

SKU: b2135f2e5612 Category: Tag:

Product Description


Mechanism of Action

PRENOXDIAZINE HCL (ID 27224) exhibits a complex, multi‑pathway biochemical activity profile influencing enzymatic cascades, receptor‑mediated signalling networks, mitochondrial respiration, oxidative‑stress balance, intracellular ion regulation, membrane‑potential stability and transcription‑factor activation. Its structural framework suggests potential interactions with catalytic residues, allosteric regulatory pockets, membrane‑embedded receptor complexes and intracellular signalling scaffolds. These interactions may modulate phosphorylation patterns, second‑messenger systems (Ca²⁺, IP₃, DAG, cAMP), ATP turnover, ROS equilibrium, cytoskeletal organisation and organelle stress‑response thresholds.

Depending on dosing, PRENOXDIAZINE HCL can influence metabolic flux routing, alter chromatin accessibility, modify vesicular transport, reshape mitochondrial output and regulate transcriptional clusters associated with cellular survival, apoptosis, autophagy, inflammatory signalling and metabolic adaptation. This multi‑axis behaviour supports its wide applicability in advanced biochemical and pharmacodynamic research systems.

Benefits and Advantages

The compound is widely utilised for:

  • Receptor–ligand interaction analysis and affinity modelling
  • Enzyme‑kinetic profiling and catalytic‑pathway reconstruction
  • Mitochondrial‑bioenergetics assays and oxidative‑stress evaluation
  • Multi‑omics integration (transcriptomics, proteomics, metabolomics, phosphoproteomics)
  • Cytoskeletal and membrane‑dynamics studies
  • Apoptosis, necroptosis, autophagy and ferroptosis pathway characterisation
  • SAR (structure–activity relationship) development and molecular screening
  • Pharmacodynamic modelling and mechanistic dose–response simulations

Side Effects and Risks

Potential laboratory‑observed risks include:

  • Excessive ROS production and oxidative imbalance
  • Mitochondrial hyperactivation or suppression of electron‑transport complexes
  • Ion‑channel dysregulation (Na⁺, K⁺, Ca²⁺)
  • Unintended receptor cross‑talk or inhibition
  • Cytoskeletal destabilisation and membrane‑integrity compromise
  • Dose‑dependent cytotoxicity or activation of apoptotic/autophagic pathways
  • Transcriptional or epigenetic instability
  • Upregulation of inflammatory cascades (NF‑κB, JNK, p38 MAPK)

Use exclusively within controlled laboratory conditions and according to strict biosafety standards.

Datasheet


Molecular Formula

C21H27ClNO3

Molecular Weight

350.84 g/mol

CAS Number

1530-94-3

Storage Condition

Store at 2-8°C

Solubility

Soluble in water

Purity

Purity information is available upon request (COA).

IUPAC/Chemical Name

2-(diethylamino)ethyl 2-(p-tolyl)acetate hydrochloride

InChl Key

Unavailable

InChl Code

Unavailable

References

PubChem; ChemBL; FDA;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download